WASHINGTON, Sept 25 (Reuters) - Genentech Inc. has added warnings about a rare brain condition called reversible posterior leukoencephalopathy syndrome, or RPLS, in patients using its cancer drug Avastin, the U.S. Food and Drug Administration said on Monday.
